XBiotech (NASDAQ:XBIT) Share Price Passes Below 50-Day Moving Average - Time to Sell?

XBiotech Inc. (NASDAQ:XBIT - Get Free Report) shares passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.44 and traded as low as $2.40. XBiotech shares last traded at $2.53, with a volume of 74,129 shares.Analysts Set New Price TargetsSeparately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of XBiotech in a research note on Monday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of "Sell".Get Our Latest Analysis on XBiotechXBiotech Price PerformanceThe firm's 50 day moving average price is $2.44 and its 200-day moving average price is $2.74. The stock has a market cap of $77.14 million, a P/E ratio of -2.64 and a beta of 0.78. XBiotech (NASDAQ:XBIT - Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter. Institutional Trading of XBiotechA number of institutional investors have recently made changes to their positions in XBIT. BNP Paribas Financial Markets grew its stake in shares of XBiotech by 27.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 20,729 shares of the biopharmaceutical company's stock valued at $62,000 after purchasing an additional 4,416 shares during the period. Bank of America Corp DE boosted its holdings in shares of XBiotech by 41.5% in the second quarter. Bank of America Corp DE now owns 18,208 shares of the biopharmaceutical company's stock worth $54,000 after buying an additional 5,344 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of XBiotech by 15.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company's stock worth $218,000 after buying an additional 8,918 shares during the last quarter. Citadel Advisors LLC grew its position in XBiotech by 31.8% during the third quarter. Citadel Advisors LLC now owns 42,816 shares of the biopharmaceutical company's stock valued at $114,000 after buying an additional 10,333 shares during the period. Finally, Hsbc Holdings PLC purchased a new stake in XBiotech during the first quarter valued at approximately $52,000. Hedge funds and other institutional investors own 55.70% of the company's stock. About XBiotech (Get Free Report)XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.Read MoreFive stocks we like better than XBiotech3 Natural Gas Stocks That Offer Great Dividend YieldsBroadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500The Top 3 Healthcare Dividend Stocks to Buy and HoldForget the Chips: 4 Industrial Plays for the AI ReboundWhat is a Special Dividend?MongoDB Could Hit Record Highs—But You’ll Need to Move FastThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in XBiotech Right Now?Before you consider XBiotech, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.While XBiotech currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here